Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07809178
Active, not recruiting Observational

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

NCT07809178 · tracked via the Priya Life Science China tracker
Sponsor
Cheng sen
Phase
Observational
Started
2026-10-20
Last updated
2026-10-21

Condition(s) studied

Unruptured Intracranial AneurysmsPituitary Neuroendocrine TumorCraniopharyngiomaMeningiomaGerminomaRathke Cleft CystsChordomaOptic Pathway GliomaHypothalamic Neoplasms

Investigational drug(s) / intervention(s)

Tumor resection followed by aneurysm treatmentAneurysm treatment followed by tumor resectionObservation

Tumor resection followed by aneurysm treatment: Tumor resection followed by aneurysm treatment

Aneurysm treatment followed by tumor resection: Aneurysm treatment followed by tumor resection

Observation: Tumor resection without aneurysm treatment but observation

Study summary

The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm. 2. Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment. 3. Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only. 4. The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment. 5. Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial. Exclusion Criteria: 1. Patients with recurrent sella region tumors. 2. Patients with previously treated intracranial aneurysm. 3. Pregnant or breastfeeding women. 4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.

Primary outcome measure(s)

  • Aneurysm progression — From enrollment to the end of treatment at 24 months
    The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status
  • Tumor related complication and progression — From enrollment to the end of treatment at 24 months
    The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital affiliated to Capital Medical University Beijing China

Other trials for the same condition

3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features Recruiting
Selumetinib for NF2-Related Schwannomatosis Starting soon
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma Active, not recruiting
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients Recruiting
Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07809178 on ClinicalTrials.gov ↗ ← All trials in China